Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 8-K (Current Report)
Date: January 21, 2016
Event: Regulation FD Disclosure regarding the announcement of topline results for two Phase 3 clinical studies (FORWARD-3 and FORWARD-4) of the investigational drug ALKS 5461 for the treatment of major depressive disorder.
Key Financial Metrics
This filing is a disclosure of clinical trial results and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the completion and announcement of topline data for the FORWARD-3 and FORWARD-4 Phase 3 studies. No financial performance changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
Outlook: The filing includes forward-looking statements regarding the therapeutic value, development, regulatory plans, and commercial potential of ALKS 5461.
Risks and Uncertainties: Management highlights significant risks, including:
- Whether preclinical and clinical results will predict future study outcomes.
- Potential delays or failure to complete future clinical trials.
- Changes in the cost, scope, and duration of the development program.
- Possibility that ALKS 5461 may be shown to be ineffective or unsafe.
- Uncertainty regarding meeting regulatory requirements for approval.
- Timeliness of regulatory submissions.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific topline data of the FORWARD-3 and FORWARD-4 studies.
- Verify the statistical significance and clinical relevance of the ALKS 5461 results in the context of major depressive disorder.
- Consult the most recent Form 10-Q (ended Sept. 30, 2015) and Form 10-K (ended Dec. 31, 2014) for detailed financial health and comprehensive risk factors.
- Monitor future filings for updates on regulatory submission timelines and potential changes to the development program scope.